Upcoming resource upgrade, list change, and permit hearing Decision on permit expected to come in Ma...
Redeye comments on the decision by CMS to decrease the average rate for 2024 under the Hospital Outp...
Redeye views the Q3 report from Moberg Pharma as very much in line with what was expected.
Redeye ceases its coverage of Alelion following the bankruptcy and delisting of the shares from Nasd...
Following today's approval from the NFSA, Lifecare has received all necessary approvals to commence ...
STENOCARE announced on November 6th an updated guidance for 2023 and 2024 as well as sales in Q3-23,...
TCECUR publicerade den 6 november bolagets Q3-rapport och visar på fortsatta framsteg.
Redeye ger en kort kommentar om försäljningssiffrorna för Leqembi under Q3.
Redeye saw a report that came in more or less as expected.
Redeye comments on BeammWave's report which we state was mostly in line with estiamtes.
Redeye provides an initial take on Enzymatica’s Q3 2023 report.
XVIVO’s future competitor in both the US Heart, Lung and Liver segment reported strong growth late y...
Cibus posted Q3 net operating income of EUR 31.0m, up 18% y/y but included as much as EUR 2.
Redeye comments on Gasporox Q3 2023 report which came in below estimates.
Redeye comments on Better Collective’s acquisition of Playmaker Capital, which is a Toronto-based di...
Q3 EBITDA of 16.4m vs ABGSCe 15.4m Production guidance narrowed Only minor estimate changes expected...
Callidita’s strict Tarpeyo (US) product growth is 130% in Q3, and the recorded Q3 sales are 12% belo...
NoHo Partners reported Q3 EBIT of EUR 8.7m, -5% versus Vara consensus and +1% versus our estimate.
Exel has taken actions to recover earnings. In our view wind power orders should drive at least some...
